AUTL vs. BCRX, SRRK, MESO, IMTX, RLAY, CGEM, RGNX, VIR, CRGX, and FDMT
Should you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include BioCryst Pharmaceuticals (BCRX), Scholar Rock (SRRK), Mesoblast (MESO), Immatics (IMTX), Relay Therapeutics (RLAY), Cullinan Oncology (CGEM), REGENXBIO (RGNX), Vir Biotechnology (VIR), CARGO Therapeutics (CRGX), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "biological products, except diagnostic" industry.
BioCryst Pharmaceuticals (NASDAQ:BCRX) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability, risk and community ranking.
BioCryst Pharmaceuticals has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.
BioCryst Pharmaceuticals received 259 more outperform votes than Autolus Therapeutics when rated by MarketBeat users. However, 67.08% of users gave Autolus Therapeutics an outperform vote while only 66.43% of users gave BioCryst Pharmaceuticals an outperform vote.
Autolus Therapeutics has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -58.69%. Autolus Therapeutics' return on equity of 0.00% beat BioCryst Pharmaceuticals' return on equity.
BioCryst Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 163.16%. Autolus Therapeutics has a consensus price target of $8.70, indicating a potential upside of 118.05%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe BioCryst Pharmaceuticals is more favorable than Autolus Therapeutics.
In the previous week, BioCryst Pharmaceuticals had 45 more articles in the media than Autolus Therapeutics. MarketBeat recorded 49 mentions for BioCryst Pharmaceuticals and 4 mentions for Autolus Therapeutics. BioCryst Pharmaceuticals' average media sentiment score of 1.18 beat Autolus Therapeutics' score of 0.56 indicating that Autolus Therapeutics is being referred to more favorably in the news media.
Autolus Therapeutics has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.
85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 4.4% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
BioCryst Pharmaceuticals beats Autolus Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Autolus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Autolus Therapeutics Competitors List
Related Companies and Tools
